NCT02669667View on ClinicalTrials.gov

Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 18, 2016

Primary Completion Date

November 17, 2016

Study Completion Date

June 12, 2017

Conditions
SafetyHealthy Subjects
Interventions
DRUG

MEDI9314

single dose of MEDI9314

DRUG

placebo

single dose of placebo

Trial Locations (2)

91206

Research Site, Glendale

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT02669667 - Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects | Biotech Hunter | Biotech Hunter